Floatz logo

FLUOROURACILUM

Recurrent Colon Cancer

AkesoSmall moleculePhase 4 / ApprovedActive
A
82/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
74/ 100
Competitive Position
95/ 100

Competitive context

157 Active assets in the Recurrent Colon Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
Fudan University
Phase 3BBB
Floxuridine
City of Hope Medical Center
Phase 2BBB
FLUOROURACILUM
Akeso
Phase 4BB
Eloxatin
Sun Yat-sen University
Phase 3BB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

FLUOROURACILUM is also rated in:

Unresectable or Metastatic Colorectal CancerDormant
BBB
Indicative ·
79 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
colon adenocarcinomaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →